semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Sclerosis, Relapsing-Remitting Patients receiving at least 11 infusions of natalizumab as disease-modifying monotherapy for RRMS that is consistent with the approved dosing  Patients for whom the NTZ infusion history and/or MRI and clinical history is not available Patients with dosing gap defined as >=12 weeks between any two doses Patients with over dose defined as <3 weeks between any two doses Pregnancy during the follow-up period
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Multiple Sclerosis Acceptance and signature of informed consent Age between 18 and 80 years old, both included Patients with relapsing remitting multiple sclerosis (RRMS), progressive secondary (SP) and primary progressive (PP), with spasticity resistant to usual treatment, either because of the severity of the spasticity or because of intolerance to side effects Outpatients with spastic paraparesis that causes gait deficiency Patients with an EDSS score between 2 and 6, both included Patients with segmental involvement in MAS >1 in two or more muscle groups in the lower extremities Absence of cognitive disability. Score less than 5 on the SPMSQ scale of Pfeiffer Possibility of carrying out the treatment (method of administration, scheduled visits) and scales correctly Women of childbearing potential should use an effective contraceptive method (hormonal contraceptives, intrauterine device, condom) or refrain from having sex in order not to get pregnant. A woman is considered to be fertile after menarche and to become postmenopausal, unless she has undergone a permanent sterilization procedure (hysterectomy, salpingectomy, bilateral oophorectomy). A postmenopausal state is defined as absence of menstruation for 12 months without an alternative medical cause  Psychiatric illness that hinders participation in the trial Comorbidity that threatens the patient's life in the short term (severe liver disease, cardiovascular disease, etc.) Osteoarticular disorder that prevents physical activity Pregnancy or lactation Lack of primary or secondary response to any type of Botulinum Toxin for the treatment of MS previously detected Sensitivity to Botulinum Toxin or to any excipient Any medical condition that, in the opinion of the investigator, may compromise compliance with the objectives and / or procedures of this protocol or preclude the administration of Botulinum Toxin Changes in the treatment regimen of any drug that directly or indirectly interferes with neuromuscular function within 4 weeks before the start of the study treatment
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Depression, Anxiety Between 18-30years old 2. Score > 10 on the QIDS or > 60 on the 3. We will use a flexible extreme groups recruitment strategy to ensure an adequate distribution of ESC scores. We will ensure that at least 62% of the sample will be composed of those scoring .5 SD above or below the mean, as measured by the NEO-PI-R. This value corresponds to the expected values assuming a normal distribution of the trait. 4. Normal or corrected to normal vision with contact lenses 5. Able to provide informed consent in English 6. Right-handed (Annett criteria)  Have a history of head trauma with loss of consciousness. 2. Have a systemic medical illness that may impact fMRI measures of cerebral blood flow. 3. Meet standard for fMRI scanning (e.g. claustrophobia, cardiac pacemakers, neural pacemakers, surgically implanted metal devices, cochlear implants, metal braces, or other MRI non-safe metal objects in the body). 4. Are pregnant (self report and tested for as part of any scan by the scanning center and not this protocol) 5. Not native English speaking or not fluent 6. Premorbid NAART IQ estimate<85; 7. Visual disturbance (worse than 20/40 Snellen visual acuity) that is not corrected 8. If have visual disturbance, only access to correction with glasses (i.e., no access to contact lenses). 9. Left/mixed handedness (Annett criteria), to ensure a uniform hemispheric dominance for interpretation of neuroimaging data 10. Active suicidal ideation in need of immediate treatment 11. Scoring below the cutoffs on both the QIDS and the 12. History of alcohol/substance use disorder (including nicotine) and/or illicit substance use (except cannabis) over the last 3 months, determined by the MINI. Lifetime/present cannabis use (non-disordered levels) will be allowed, given its common usage in individuals in this age range. 13. Current or past psychotic-spectrum disorder 14. History of seizures
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Diagnosed with RRMS per revised McDonald (2017) with an EDSS score ≤ 6.5 at screening Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF) Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (dimethyl fumarate or diroximel fumarate) Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study Investigator Patient has signed and understands the ICF  Diagnosis of primary progressive MS or secondary progressive MS Uncontrolled or significant medical conditions (including active infection or chronic hepatitis) which, in the opinion of the Investigator, preclude participation Patients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic hormone, β-interferon, plasma exchange, fingolimod, ozanimod, or siponimod within the 3 months prior to first dose Patients treated with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose Patients treated with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose Patients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies for MS Contraindication to or inability to undergo gadolinium-enhanced magnetic resonance imaging (MRI) scan Use of any investigational drug or experimental procedure within previous 6 months that would interfere with the assessment of ANK-700 Patients who are pregnant or breastfeeding
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Subjects with a documented diagnosis of relapsing-remitting MS according to the Mc Donald (2005) and with EDSS achievement of 0-3.5 according to the modified Kurtzke's EDSS (Expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis  Patients in whom the clinical course of the disease is characterized by disease progression Patients with relapsing-remitting MS who have started drug therapy with corticosteroids Patients with metals in the body (e.g. pacemaker, dentures) Patients with new pregnancies (verbally confirmed) Patients with new head trauma Subjects unwilling to sign a consent or follow study procedures
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lumbar Spinal Stenosis Low Back Pain Adults aged 18 years or older Previous diagnosis of lumbar spinal stenosis, mild-severe lumbar central canal stenosis identified by MRI or CT scan Symptoms Lower extremity symptoms consistent with neurogenic claudication Pain, weakness &/or numbness triggered by standing or walking, and relieved by sitting Must be able to read English and complete questionnaire Was prescribed Misoprostol specifically for lumbar spinal stenosis  Cognitive impairment that renders the patient unable to give informed consent or provide accurate data Clinical co-morbidities that could interfere with the collection of data concerning pain and function Severe vascular, pulmonary, or coronary artery disease that limits ambulation including recent myocardial infarction (within 6 months) Spinal instability requiring surgical fusion Severe osteoporosis as defined by multiple compression fractures or a fracture at the same level as the stenosis Metastatic cancer Excessive alcohol consumption or evidence of non-prescribed or illegal drug use Pregnancy Concordant pain with internal rotation of the hip (or known hip joint pathology) Active local or systemic infection
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthroplasty, Replacement, Knee Rehabilitation Hip Arthrosis The patient is aged 18 years or older, has a Belgian National Number, is insured by a Belgian sickness fund, and is not staying in a nursing home or long term rehabilitation centre. 2. The patient has sufficient knowledge of Dutch, French, German or English. 3. The patient has a planned date within the next 8 weeks for a primary unilateral unicompartmental knee arthroplasty (UKA); a bicompartmental knee arthroplasty, (BKA), consisting of either two UKA or a UKA and a patellar replacement; or a total knee arthroplasty (TKA) or a total hip arthroplasty (THA). 4. The patient is not planned to have a peri-operative procedure (e.g. intra-articular catheter) or postoperative procedure that is expected to significantly impact the rehabilitation in and out of hospital. 5. In the 6 months after arthroplasty the patient is not planned to have surgery that may impact the arthroplasty rehabilitation. 6. The patient is not suffering from a medical condition (e.g. Parkinson, multiple sclerosis, cerebrovascular accident) that is expected to significantly impact the rehabilitation or that constitutes a contra-indication for the use of the mobile application. 7. The patient confirms to have easy and daily access to the internet, a mobile phone, a personal email address and a computer, tablet or smartphone, now and over the next 8 months. 8. The patient does not upfront the possibility whereby part of the rehabilitation is performed without a physical therapist physically being present. 9. The patient is willing to complete online the patient reported outcomes and is aware that if he/she fails in this computer literacy test (performed before randomization) he/she will not be randomized and hence not included in the study. He/she will receive usual rehabilitation care
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Myelopathy Spinal Cord Diseases Patients suffering from degenerative cervical myelopathy as per established who have granted informed consent to participate in the trial Have a preoperative mJOA score ≥8 and ≤14 Scheduled for first surgical decompression as part of usual NHS clinical practice  Previous surgery for DCM DCM symptoms due to cervical trauma (at the discretion of the investigator) Hypersensitivity to Ibudilast or any of the formulation components Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation including ALP> 1.5x ULN; ALT or AST > 2x ULN; GGT > 3x ULN Active malignancy defined as history of invasive malignancy, except if the patient has received treatment and displayed no clinical signs and symptoms for at least five years Recent history (less than 3 years) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation Female patients with child bearing potential who are unwilling or unable to use reliable methods of contraception Female patients who are pregnant, lactating or planning pregnancy during the course of the trial Inability to comply with study procedures, IMP regime or follow-up schedule Unable to take a gelatin based product
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Stroke Neglect A person with left hemiplegia who was found to have a stroke by MRI or CT. 2. A person who has been confirmed to have unilateral neglect (BIT 196 or less, or each subtest cut off or less) 3. A person who has enough cognitive ability to receive virtual reality training. (In case of more than 20 points in MMSE) 4. Those within 3 months of onset  Those with a history of recurring brain damage 2. hemianopsia 3. When there is a disorder in the movement of the neck due to orthopedic problems 4. Someone has vision and hearing problems during evaluation and treatment 5. difficult to maintain a sitting position in a chair with back and armrests 6. other diseases that may affect your general cognitive decline 7. who disagree with this study
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chest Pain Patient presenting to the emergency department with chest pain  ST elevation myocardial infarction Pneumonia, pneumothorax, pulmonary embolism and esophageal rupture Patients under 18 years of age Pregnant patients Patients who do not want to be included in the study